Self-funded BMS project: Understanding and targeting the hypoxic response in acute myeloid leukaemia (AML)

Hypoxia-inducible factor (HIF) is a master regulator of transcription, and its function is centrally involved in both normal haematopoiesis and in malignant transformation of blood cells causing acute myeloid leukaemia (AML). Strikingly, in different patients, and in different mouse models of AML, HIF can function to either enhance or suppress the initiation and progression of this cancer. Using primary haematopoietic stem cells (HSCs), this project will identify the factors which direct the transcriptional activity of HIF and create the contexts which dictate how HIF function is programmed in normal and cancerous HSCs. This knowledge will, for the first time, unlock the potential of developing new therapies which can target or rewire HIF function in AML, and will inform our understanding of how HIF functions in cancers of other origin.

The York Biomedical Research Institute at the University of York is committed to recruiting extraordinary future scientists regardless of age, ethnicity, gender, gender identity, disability, sexual orientation or career pathway to date. We understand that commitment and excellence can be shown in many ways and have built our recruitment process to reflect this. We welcome applicants from all backgrounds, particularly those underrepresented in science, who have curiosity, creativity and a drive to learn new skills.

Entry Requirements: Students with, or expecting to gain, at least an upper second class honours degree, or equivalent, are invited to apply. The interdisciplinary nature of this programme means that we welcome applications from students with backgrounds in any biological, chemical, and/or physical science, or students with mathematical backgrounds who are interested in using their skills in addressing biological questions. 

Programme: PhD in Biomedical Science (3 years)

Start Date: 1st October 2022 (the student will be affiliated with the Department of Biology)